echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Transl Oncol: Metformin-salicylic acid treatment can improve prostate cancer treatment

    Transl Oncol: Metformin-salicylic acid treatment can improve prostate cancer treatment

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Prostate cancer (PrCa) is the most common male cancer in Western countries
    .
    Radiotherapy (RT) is the main treatment for all stages of prostate cancer, but prostate tumors are resistant to this treatment

    .
    Increasing the radiation dose can improve local disease control, but it can cause bladder and intestinal toxicity

    .
    Therefore, there is a need for methods that can increase the sensitivity of radiotherapy

    .

    Anti- diabetic drugs metformin (MET) and aspirin metabolite salicylate (SAL) can activate AMP protein kinase (AMPK) and inhibit adipogenesis (DNL) and mammalian rapamycin (mTOR) pathways, and can reduce in vitro Proliferation of PrCa
    .

    Diabetic metformin

    Recently, researchers from Canada published an article in "Transl Oncol", investigating whether MET+SAL treatment can enhance PrCa tumor suppression and improve the response to RT
    .

    Investigated whether MET+SAL treatment can enhance the PrCa tumor suppression effect and improve the response to RT.
    Investigate whether MET+SAL treatment can enhance the PrCa tumor suppression effect and improve the response to RT.

    The researchers used androgen-sensitive (22RV1) and resistant (PC3, DU-145) PrCa cells and PC3 xenografts to investigate whether MET+SAL treatment is better than MET or SAL alone in inhibiting PrCa cells and Tumor activity
    .
    The mechanism of action was investigated by analyzing signal pathways, mitochondrial respiration and DNL activity determination

    .

    It was found that PrCa cells are resistant to clinical doses of MET
    .
    MET+SAL treatment can produce synergistic anti-proliferative activity at clinical doses and enhance the anti-proliferative effect of RT

    .
    The above effects are related to the inhibition of oxygen consumption rate (OCR), the activation of AMPK, the inhibition of acetyl-CoA carboxylase (ACC)-DNL and mTOR-p70s6k/4EBP1 and HIF1α pathways

    .
    MET+SAL reduces the growth of non-radiotherapy tumors and enhances the effect of RT

    .

    Metformin + salicylic acid can inhibit tumor growth and DNA replication

    Metformin + salicylic acid can inhibit tumor growth and DNA replication

    In summary, MET+SAL treatment can inhibit the proliferation of PrCa cells and tumor growth, and enhance the response to RT at clinical doses
    .
    MET and SAL are widely used safely and cheaply.
    Their data supports further investigation in PrCa clinical trials

    .

    MET+SAL treatment can inhibit the proliferation of PrCa cells and tumor growth, and enhance the response to RT at clinical doses MET+SAL treatment can inhibit the proliferation of PrCa cells and tumor growth, and enhance the response to RT at clinical doses

    Original source:

    Original source:

    Evangelia E Tsakiridis, Lindsay Broadfield, Katarina Marcinko et al.
    Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses .
    Transl Oncol.
    Aug 2021

    Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.